Speciality: Therapeutics
|
|
- Stewart Manning
- 5 years ago
- Views:
Transcription
1 Gentamicin Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Directorate & Speciality Date of submission May 2017 Date on which guideline must be May 2020 reviewed (one to five years) Explicit definition of patient group to which it applies (e.g. inclusion and exclusion criteria, diagnosis) Abstract Key Words Guideline for the treatment of children and young people with intravenous gentamicin Dr Mamatha Mallya SpR Paediatrics Andrew Wignell, Senior Clinical Pharmacist, Paediatrics Dr Meeta Mallik, Consultant Paediatric Nephrologist Directorate: Family Health Children Speciality: Therapeutics Children and young people aged 0-18 yrs requiring intravenous gentamicin treatment Gentamicin, intravenous antibiotics monitoring, nephrotoxic, ototoxic, TDM Statement of the evidence base of the guideline has the guideline been peer reviewed by colleagues? 1a meta analysis of randomised controlled trials 2a at least one well-designed controlled study without randomisation 2b at least one other type of well-designed quasi-experimental study 3 well designed non-experimental descriptive studies (ie comparative / correlation and case studies) 4 expert committee reports or opinions and / or clinical experiences of respected authorities 5 recommended best practise based on the clinical experience of the guideline developer Consultation Process Clinicians and healthcare professionals caring for children and young people (0-18yrs) who require treatment with intravenous gentamicin Target audience Paediatric Clinical Guidelines Group This guideline has been registered with the trust. However, clinical guidelines are guidelines only. The interpretation and application of clinical guidelines will remain the responsibility of the individual clinician. If in doubt contact a senior colleague or expert. Caution is advised when using guidelines after the review date.
2 Document Control Document Amendment Record Version Issue Date Author V1 Dec 2010 V2 Jun 2014 Andy Lunn V3 May 2017 Peter Foxon General Notes: Summary of changes for new version: 1) Table 4: Change in egfr ranges to fit in with CKD staging 2) Table 4: Removal of dose ranges for reduced GFR. Replacement with definitive values 3) Removal of sample timing recommendations due to 24 hour lab availability
3 Gentamicin Introduction Background Gentamicin is a broad spectrum aminoglycoside antibiotic. It is active against some gram positive and many gram negative organisms: Staphylococcus aureus (including MRSA), Escherichia coli, Pseudomonas aeruginosa and Klebsiella sp. It is inactive against anaerobes and has poor activity against Haemolytic Streptococci, Pneumococci, Enterococcus and H.influenza. Once daily dosing (ODD) is an easier and possibly superior alternative to multiple daily dosing (MDD) and is recommended for most paediatric patients Benefits of ODD include, enhanced concentration- dependent bactericidal activity, post antibiotic effect (PAE), decreased risk of adaptive resistance and less accumulation in the renal tubules and inner ear. Extended dosing profile is recommended for neonates Post Antibiotic Effect (PAE) This refers to suppression of bacterial growth even when no extracellular drug is present, allowing continued efficacy even when serum concentrations fall below the expected minimum inhibitory concentration (MIC). The PAE is longer with a higher aminoglycoside peak serum concentration and in the presence of neutrophils. Toxicity Excretion of Gentamicin is principally via the kidney. The two most important adverse effects are nephrotoxicity and ototoxicity. Both relate to serum drug concentration and duration of therapy. The rate of uptake of gentamicin into the renal tissue is related to the time of exposure to higher levels rather than the absolute concentration. Therefore, giving high doses less frequently may reduce toxicity Monitoring of serum gentamicin levels, renal function (urea, electrolytes and creatinine) and fluid balance is essential
4 Once Daily Gentamicin Regimen Indications Meningitis/Sepsis in neonates Febrile Neutropenia (stat dose then review see oncology guideline in addition) Surgical conditions- perforated or gangrenous appendicitis (on microbiology advice) Urosepsis- see Paediatric UTI Guideline Exclusion Criteria 1) Multiple daily gentamicin dosing regimens are still recommended for patients in the following categories (please refer to the BNFc for dosing and monitoring recommendations and liaise with pharmacist) Endocarditis Extensive burns Concurrent pregnancy Ascites/excessive third-space volume Where intramuscular gentamicin is necessary (i.e. where intravenous access is not possible) 2) Increased risk of gentamicin toxicity. Patients in the categories below are at increased risk of gentamicin toxicity. The use of gentamicin should be discussed with the patient s consultant and where appropriate an alternative antibiotic should be considered. The gentamicin dosing and monitoring regimen will need to be adjusted (see dosing in renal impairment section later). Patients with acute kidney injury or chronic renal impairment (egfr < 90 ml/min/1.73 m 2 1 ). Renal transplant patients Dialysis patients 3) 4) Patients with myasthenia gravis - gentamicin may impair neuromuscular transmission and must not be given in myasthenia gravis. Neonates with a postmenstrual age of less than 32 weeks - please refer to Neonatal Service clinical guideline (no. 27), the interval between doses is increased to 36 hours. Cautions Renal function and gentamicin levels should be monitored very carefully in patients who are receiving additional nephrotoxic drugs such as: Cyclosporine Tacrolimus Aciclovir Amphotericin NSAIDs. Gentamicin should preferably not be given with other ototoxic drugs (e.g. Furosemide). If concomitant use cannot be avoided, administration should be staggered. 1 egfr (ml/min/1.73 m2) = (height in cm x k) / Creatinine (µmol/l) where k=36 in males 13 years or over and 30 in all other cases (Local modification of Schwartz-Haycock formula)
5 Dosing Once daily dose regimen Most side effects are dose related, therefore care must be taken with dosage and whenever possible treatment should not exceed 7 days. Table 1: Once daily gentamicin recommended dosages and administration Age Once Daily Dose Administration Neonates 4 mg/kg Slow bolus over 3 mins or (< 28 days) intravenously infusion over 30 mins Children 7 mg/kg Infusion over at least 30 (1 month- 18 years) intravenously mins (maximum 500mg) When prescribing gentamicin - o Round doses down to the nearest 0.5 mg for neonates and to the nearest 1mg for older children o Use the 24 hour clock and avoid midday and midnight o Indicate the timing of levels clearly on the drug chart o Initially prescribe the first 3 doses only to ensure that levels are checked Dosing in obese patients Aminoglycosides distribute poorly into adipose tissue. Ideal body weight (IBW) should be used if the child is obese (extrapolate estimated IBW from the height centiles on growth chart) Administration Parenteral gentamicin should be administered via the intravenous route where possible. Interruptions during the preparation and administration of gentamicin should be minimised, staff should not be disturbed A double checking prompt should be used during the preparation and administration of gentamicin The prescribed dose of gentamicin should be given within 1 hour of the prescribed time. If the dose given is delayed, the prescription chart should be re-written with the exact time of the dose given
6 Monitoring All patients with normal baseline renal function receiving once daily gentamicin should have: Measurement of renal function (creatinine, urea and electrolytes) at baseline and at least twice weekly thereafter. Measurement of a pre-dose gentamicin level taken before the 2nd dose. Measurement of fluid balance and daily weight where possible. Sampling o o o o Take a blood sample (minimum of 0.5 ml in gold top serum separator tubes (preferred) or red top) 18 to 24 hours after the first dose If sampling from a central venous line, do not sample from the same lumen through which gentamicin was administered, peripheral venous/ finger prick sampling may therefore be required instead This sample should be labelled as a "Pre-dose" Post-dose samples are NOT required for those on once daily dosing Request cards These must include the following information to allow accurate interpretation of the assay result: Patient Details Drug Details Sample Details Name Antibiotic Date and time of sample Hospital number Dose Date and time of last Date of birth Frequency dose Last creatinine and date Indication Type of sample (random, pre-dose, post-dose) Failure to provide this information may result in the sample being rejected by the lab, or incorrect interpretation of the assay result. Target Gentamicin Levels (once daily dose regimen) Table 2: Target pre-dose levels Neonates <28 days Age Children 1month- 18 years Target Pre-Dose (trough) Level < 2 mg/l < 1 mg/l In children with normal renal function (egfr >90 ml/min/1.73m 2 ) and good urine output, measure gentamicin pre-dose level before the 2rd dose and the dose can be given without waiting for the result. If renal function deteriorates (10 point rise in creatinine in µmol/l from baseline), then further doses of gentamicin should be withheld until the trough level is available for review (see below). If pre dose level is within target range Continue current regimen. Further pre-dose levels must be performed every 3-4 days so long as renal function is stable. Adjustments required for higher levels are summarised in the table below.
7 Table 3: Management of pre-dose gentamicin level results Age Neonate <28 days Child 1month 18 years Gentamicin Pre-Dose Level and Response < 2mg/L 2-3 mg/l >3 mg/l < 1mg/L 1-2 mg/l >2 mg/l Action Continue current regimen. Repeat level after 3-4 days provided renal function stable If renal function stable, increase dosing interval to 36 hourly and repeat levels with the next dose (giving the dose). Review the need for gentamicin therapy, assess renal function. Withhold further doses until discussed with microbiology and levels within target trough range (repeat after 24 hours). Renal Function Monitoring All children should have creatinine and U+Es checked at least thrice weekly- ideally at baseline, at the same time as the first level and once thereafter. The egfr should also be calculated to ensure normal renal function on each occasion. Measure fluid balance and daily weight (where possible) in all children. If any acute deterioration in renal function (10 µmol/l or greater rise in creatinine from baseline) occurs a pre-dose level should be taken before the next dose is due and the dose withheld. o The result must be reviewed before any further gentamicin is given (unless on the direct advice of the patient s consultant, usually in discussion with microbiology). o The requirement for gentamicin should be reassessed and further doses should only be given once the serum level is <1mg/L. Renal Impairment In patients with renal impairment, give a one-off dose according to egfr, as below. egfr (ml/min/1.73m 2 ) Table 4: Gentamicin dosing in patients with renal impairment mg/kg mg/kg mg/kg <15 / Dialysis patient 2 mg/kg One-off Gentamicin Dose Check gentamicin levels 24 hours after the first dose and await the result. If the level is 1 mg/l, recheck levels after hours. Do not give any further doses of gentamicin until the level is <1 mg/l. Gentamicin is removed by dialysis. In haemodialysis patients the dose should be given after dialysis.
8 Indications for Hearing Test New onset Nephrotoxicity Subsequent gentamicin dose administration despite high trough level Longer duration of therapy (> than 7 days) Family history of ototoxicity Concomitant use of Furosemide or other ototoxic drugs Audit Criteria Aminoglycoside fluid balance audit (attached) Gentamicin care bundle compliance chart (attached) Standard: All patients on an aminoglycoside will have their renal function checked at least three times a week and their fluid intake and output accurately monitored to allow early detection of nephrotoxicity. Exceptions to strict fluid balance monitoring include: Oncology patients who leave the ward between doses of antibiotics providing they are well and have normal renal function (must be agreed with registrar or consultant). Cystic fibrosis patients who are well and receiving planned treatment and have normal renal function (must be agreed with registrar or consultant). Breast fed babies whose intake cannot be measured in which case recording all wet nappies is sufficient rather than weighing nappies. Haemodialysis patients who are well enough to be at home between dialysis sessions Patients in the above groups should have their weight measured daily or each time they come to the hospital. References BNF for children Safer use of intravenous gentamicin for neonates: National Patient Safety Agency Once daily Gentamicin in adults Trust Guidelines Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Smyth AR, Bhatt J, Cochrane Database Syst. Rev Jan 20;(1):CD Extended Interval Aminoglycoside administration for children :A meta-analysis. Contopoulos- Ioannidis et al. Pediatrics (1) e111-8 Nottingham Neonatal Service Clinical Guideline No Gentamicin Use The Renal Drug Database, accessed via renaldrugdatabase.com on 9 th Mat 2017
Patients. Excludes paediatrics, neonates.
Full title of guideline Author Division & Speciality Scope Gentamicin Prescribing Guideline For Adult Patients Annette Clarkson, Specialist Clinical Pharmacist Antimicrobials and Infection Control All
More informationONCE DAILY GENTAMICIN DOSING AND MONITORING IN ADULTS POLICY QUESTIONS AND ANSWERS
ONCE DAILY GENTAMICIN DOSING AND MONITORING IN ADULTS POLICY QUESTIONS AND ANSWERS Contents 1. How to I calculate a gentamicin dose?... 2 2. How do I prescribe gentamicin on the cardex?... 2 3. Can I give
More informationANTIBIOTIC PRESCRIBING POLICY FOR DIABETIC FOOT DISEASE IN SECONDARY CARE
ANTIBIOTIC PRESCRIBING POLICY FOR DIABETIC FOOT DISEASE IN SECONDARY CARE Version 1.0 Date ratified June 2009 Review date June 2011 Ratified by Authors Consultation Nottingham Antibiotic Guidelines Committee
More informationThis controlled document shall not be copied in part or whole without the express permission of the author or the author s representative.
This document is also available in large print and other formats and languages, upon request. Please call NHS Grampian Corporate Communications on (01224) 551116 or (01224) 552245. This controlled document
More informationThese recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017.
Antibiotic regimens for suspected hospital-acquired infection (HAI) outside the Paediatric Intensive Care Unit at Red Cross War Memorial Children s Hospital (RCWMCH) Lead author: Brian Eley Contributing
More informationPharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring. Janis Chan Pharmacist, UCH 2008
Pharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring Janis Chan Pharmacist, UCH 25-4-2008 2008 Aminoglycosides (AG) 1. Gentamicin 2. Amikacin 3. Streptomycin 4. Neomycin
More information1 TRADE NAME OF THE MEDICINAL PRODUCT. Gentamicin Paediatric 20mg/2ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
1 TRADE NAME OF THE MEDICINAL PRODUCT Gentamicin Paediatric 20mg/2ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 2ml contains 20mg of Gentamicin as Gentamicin Sulfate Excipient
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
Antibiotic treatment and monitoring for suspected or confirmed early-onset neonatal infection bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to
More informationGUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
Version 3.1 GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Date ratified June 2008 Updated March 2009 Review date June 2010 Ratified by Authors Consultation Evidence base Changes
More informationAcute Pyelonephritis POAC Guideline
Acute Pyelonephritis POAC Guideline Refer full regional pathway http://aucklandregion.healthpathways.org.nz/33444 EXCLUSION CRITERIA: COMPLICATED PYELONEPHRITIS Discuss with relevant specialist for advice
More informationProtein Synthesis Inhibitors
Protein Synthesis Inhibitors Assistant Professor Dr. Naza M. Ali 11 Nov 2018 Lec 7 Aminoglycosides Are structurally related two amino sugars attached by glycosidic linkages. They are bactericidal Inhibitors
More informationPATIENT INFORMATION LEAFLET GENTAMICIN 10MG/ML SOLUTION FOR INJECTION OR INFUSION. and GENTAMICIN 40MG/ML SOLUTION FOR INJECTION OR INFUSION
PATIENT INFORMATION LEAFLET GENTAMICIN 10MG/ML SOLUTION FOR INJECTION OR INFUSION and GENTAMICIN 40MG/ML SOLUTION FOR INJECTION OR INFUSION Read all of this leaflet carefully before you start taking this
More informationIntroduction to Pharmacokinetics and Pharmacodynamics
Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:
More informationSURGICAL ANTIBIOTIC PROPHYLAXIS GUIDELINES WITHIN ORTHOPAEDIC SURGERY FOR ADULT PATIENTS
SURGICAL ANTIBIOTIC PROPHYLAXIS GUIDELINES WITHIN ORTHOPAEDIC SURGERY FOR ADULT PATIENTS Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if
More informationDRUG GUIDELINE GENTAMICIN (SULFATE)
DRUG GUIDELINE GENTAMICIN (SULFATE) SCOPE (Area): FOR USE IN: All ward areas, except as outlined below EXCLUSIONS: Paediatrics (seek Paediatrician advice) SCOPE (Staff): Medical, Nursing and Pharmacy BRAND
More informationAppropriate Antimicrobial Therapy for Treatment of
Appropriate Antimicrobial Therapy for Treatment of Staphylococcus aureus infections ( MRSA ) By : A. Bojdi MD Assistant Professor Inf. Dis. Dep. Imam Reza Hosp. MUMS Antibiotics Still Miracle Drugs Paul
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationPharmacological Evaluation of Amikacin in Neonates
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUlY 1975, p. 86-90 Copyright 0 1975 American Society for Microbiology Vol. 8, No. 1 Printed in U.SA. Pharmacological Evaluation of Amikacin in Neonates JORGE B.
More informationTreatment of peritonitis in patients receiving peritoneal dialysis Antibiotic Guidelines. Contents
Treatment of peritonitis in patients receiving Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Jude Allen (Pharmacist) Additional author(s): Dr David Lewis, Dr Dimitrios Poulikakos,
More informationHealth Products Regulatory Authority
1 NAME OF THE VETERINARY MEDICINAL PRODUCT Genta 50 mg/ml solution for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active Substances Gentamicin sulphate equivalent to Gentamicin
More informationInitial Management of Febrile Neutropenia or Suspected Bacterial Infection
Initial Management of Febrile Neutropenia or Suspected Bacterial Infection Reference: Written by: Peer reviewer CG854 Dr Daniel Yeomanson Karen Whitehouse Approved: December 2014 Approved by D&TC: 14 th
More informationFACTORS AFFECTING THE POST-DIALYSIS LEVELS OF VANCOMYCIN AND GENTAMICIN IN HAEMODIALYSIS PATIENTS. Acute-Haemodialysis Team St.
FACTORS AFFECTING THE POST-DIALYSIS LEVELS OF VANCOMYCIN AND GENTAMICIN IN HAEMODIALYSIS PATIENTS. Acute-Haemodialysis Team St. Helier s Hospital Vancomycin and Gentamicin Audit Renal Unit St Helier Hospital
More informationStanding Orders for the Treatment of Outpatient Peritonitis
Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.
More informationAntibiotic Prophylaxis in Spinal Surgery Antibiotic Guidelines. Contents
Antibiotic Prophylaxis in Spinal Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): Authors Division: DCSS & Tertiary Medicine Unique
More informationStanding Orders for the Treatment of Outpatient Peritonitis
Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.
More informationProtocol for exit-site care and treatment of exit-site infections in peritoneal dialysis CONTROLLED DOCUMENT
CONTROLLED DOCUMENT Protocol for exit-site care and treatment of exit-site infections in peritoneal dialysis CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Guideline Clinical The purpose
More informationAntimicrobial Stewardship
Antimicrobial Stewardship Report: 11 th August 2016 Issue: As part of ensuring compliance with the National Safety and Quality Health Service Standards (NSQHS), Yea & District Memorial Hospital is required
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More informationClinical Practice Standard
Clinical Practice Standard 1-20-6-1-010 TITLE: INTRAVENOUS TO ORAL CONVERSION FOR ANTIMICROBIALS A printed copy of this document may not reflect the current, electronic version on OurNH. APPLICABILITY:
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More informationPharmacology Week 6 ANTIMICROBIAL AGENTS
Pharmacology Week 6 ANTIMICROBIAL AGENTS Mechanisms of antimicrobial action Mechanisms of antimicrobial action Bacteriostatic - Slow or stop bacterial growth, needs an immune system to finish off the microbe
More informationSimilar to Penicillins: -Chemically. -Mechanism of action. -Toxicity.
Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity. Cephalosporins are divided into Generations: -First generation have better activity against gram positive organisms. -Later compounds
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER Gentamicin 40 mg/ml Injection
PACKAGE LEAFLET: INFORMATION FOR THE USER Gentamicin 40 mg/ml Injection Read all of this leaflet carefully before you start using this medicine because it contains important information for you. Keep this
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/MRL/728/00-FINAL April 2000 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS STREPTOMYCIN AND
More informationIntravenous Antibiotic Therapy Information Leaflet
Scottish Adult Cystic Fibrosis Service Ninewells Hospital Dundee Intravenous Antibiotic Therapy Information Leaflet February 2008 Intravenous antibiotic therapy in cystic fibrosis Patients with cystic
More informationPharmaceutical Form Ciprofloxacin 2 mg/ml Solution for infusion. Applicant Name Strength. Ciprofloxacin Nycomed. Ciprofloxacin Nycomed
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ROUTE OF ADMINISTRATION, APPLICANT/ MARKETING AUTHORISATION HOLDER IN THE MEMBER STATES Marketing Member State Authorisation
More informationScottish Medicines Consortium
Scottish Medicines Consortium daptomycin 350mg powder for concentrate for solution for infusion (Cubicin ) Chiron Corporation Limited No. (248/06) 10 March 2006 The Scottish Medicines Consortium (SMC)
More informationAntibiotic Line Lock Guideline
Antibiotic Line Lock Guideline Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Guideline for the management of long-term catheterrelated
More informationFOLLOWING BUNDLE ADMINISTERED WITHIN ONE HOUR.
Patient label DATE and TIME: 1 REVIEW BY Emergency Department SENIOR REGISTRAR (ED BLEEP 5999) +/-Leave Proforma 2 FOLLOWING BUNDLE ADMINISTERED WITHIN ONE HOUR. Bloods for FBC, U+E, CRP, LFT s, Clotting
More informationMIACIN HIKMA PHARMACEUTICALS
09-15 MIACIN HIKMA PHARMACEUTICALS Amikacin (as sulfate) Solution for injection DESCRIPTION Amikacin sulfate is semi-synthetic aminoglycoside antibiotic derived from kanamycin. Clinical Pharmacology Intramuscular
More informationNottingham Renal and Transplant Unit
Nottingham Renal and Transplant Unit Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review date (when this version goes out
More informationGuidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults)
Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults) Community Acquired Community Acquired 1) Is it pneumonia? ie new symptoms and signs of a lower respiratory
More informationScottish Medicines Consortium
Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationRandomized Controlled Trial on Adjunctive Lavage for Severe Peritoneal Dialysis- Related Peritonitis
Randomized Controlled Trial on Adjunctive Lavage for Severe Peritoneal Dialysis- Related Peritonitis Steve SM Wong Alice Ho Miu Ling Nethersole Hospital Background PD peritonitis is a major cause of PD
More informationGuidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults)
Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults) Community Acquired Pneumonia Community Acquired Pneumonia 1) Is it pneumonia? ie new symptoms and signs of
More informationCurricular Components for Infectious Diseases EPA
Curricular Components for Infectious Diseases EPA 1. EPA Title Promoting antimicrobial stewardship based on microbiological principles 2. Description of the A key role for subspecialists is to utilize
More information* gender factor (male=1, female=0.85)
Usual Doses of Antimicrobials Typically Not Requiring Renal Adjustment Azithromycin 250 500 mg Q24 *Amphotericin B 1 3-5 mg/kg Q24 Clindamycin 600 900 mg Q8 Liposomal (Ambisome ) Doxycycline 100 mg Q12
More informationVOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559. ANTIBIOTIC 6640.* Ill
VOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559 ANTIBIOTIC 6640.* Ill BIOLOGICAL STUDIES WITH ANTIBIOTIC 6640, A NEW BROAD-SPECTRUM AMINOGLYCOSIDE ANTIBIOTIC J. Allan Waitz, Eugene L. Moss, Jr., Edwin
More informationClinical Guideline. District Infectious Diseases Management. Go to Guideline. District Infectious Diseases Management CG 18_24
Clinical Guideline District Infectious Diseases Management Sites where Clinical Guideline applies All facilities This Clinical Guideline applies to: 1. Adults Yes 2. Children up to 16 years Yes 3. Neonates
More informationGynaecological Surgery in Adults Surgical Antibiotic Prophylaxis
Gynaecological Surgery in Adults Surgical Antibiotic Prophylaxis Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review date
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE
European Medicines Agency Veterinary Medicines and Inspections EMEA/CVMP/211249/2005-FINAL July 2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE DIHYDROSTREPTOMYCIN (Extrapolation to all ruminants)
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY
More informationPIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS
PIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS The current supply of piperacillin- tazobactam should be reserved f Microbiology / Infectious Diseases approval and f neutropenic sepsis, severe sepsis
More informationAntimicrobial Stewardship Strategy: Dose optimization
Antimicrobial Stewardship Strategy: Dose optimization Review and individualization of antimicrobial dosing based on the characteristics of the patient, drug, and infection. Description This is an overview
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More informationEffective 9/25/2018. Contact for previous versions.
Pharmacokinetic and Pharmacodynamic Dose Optimization of Antibiotics (β-lactams, aminoglycosides, and ciprofloxacin) for the Treatment of Gram-Negative Infections Adult Inpatient/Emergency Department Clinical
More informationUpdate on Therapeutic Drug Monitoring - Aminoglycosides. Antimicrobial Stewardship Forum Cardiff Nov. 2nd 2015
Update on Therapeutic Drug Monitoring - Aminoglycosides Antimicrobial Stewardship Forum Cardiff Nov. 2nd 2015 Andrew Lovering Antimicrobial Reference Laboratory North Bristol NHS Trust What are common
More informationNational Antimicrobial Prescribing Survey
Indication documented Surgical prophylaxis >24 hrs Allergy mismatch Microbiology mismatch Incorrect route Incorrect dose/frequency Incorrect duration Therapeutic Guidelines Local guidelines * Non-compliant
More informationTITLE: NICU Late-Onset Sepsis Antibiotic Practice Guideline
Site: Saint Joseph Hospital - NICU Original Effective Date: 6/1/2016 Next Review Date: 6/1/2019 TITLE: Practice Guideline Purpose: Timely and appropriate treatment of late-onset sepsis with antibiotic
More informationInappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012
Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton
More informationClinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: HIM*, Medicaid
Clinical Policy: (Zyvox) Reference Number: CP.PMN.27 Effective Date: 09.01.06 Last Review Date: 02.19 Line of Business: HIM*, Medicaid Coding Implications Revision Log See Important Reminder at the end
More informationDiagnosis: Presenting signs and Symptoms include:
PERITONITIS TREATMENT PROTOCOL CARI - Caring for Australasians with Renal Impairment - CARI Guidelines complete list ISPD Guidelines: http://www.ispd.org/lang-en/treatmentguidelines/guidelines Objective
More informationAntibiotic prophylaxis guideline for colorectal, hepatobiliary and vascular surgery for adult patients.
Antibiotic prophylaxis guideline for colorectal, hepatobiliary and vascular surgery for adult patients. Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience,
More informationDuke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients
Duke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients PURPOSE Fever among neutropenic patients is common and a significant cause of morbidity
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationANTIMICROBIAL DOSING GUIDE 2013
page 1 / 5 page 2 / 5 antimicrobial dosing guide 2013 pdf Stanford Hospital & Clinics Aminoglycoside Dosing Guidelines 2013 I. DETERMINING DOSE AND CREATININE CLEARANCE: 1. Use of ideal body weight (IBW)
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cephacare flavour 50 mg tablets for cats and dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active
More informationCentral Nervous System Infections
Central Nervous System Infections Meningitis Treatment Bacterial meningitis is a MEDICAL EMERGENCY. ANTIBIOTICS SHOULD BE STARTED AS SOON AS THE POSSIBILITY OF BACTERIAL MENINGITIS BECOMES EVIDENT, IDEALLY
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.HNMC.04 Effective Date: 07.01.17 Last Review Date: 02.18 Line of Business: Medicaid - HNMC Revision Log See Important Reminder at the end of this policy for important
More informationSubmission for Reclassification
Submission for Reclassification Fucithalmic (Fusidic Acid 1% Eye Drops) From Prescription Medicine to Restricted Medicine (Pharmacist Only Medicine) CSL Biotherapies (NZ) Limited 666 Great South Road Penrose
More informationappropriate healthcare professionals employed at my pharmacy. I understand that I am
Patient Group Direction: For the supply of Silver Sulfadiazine 1% Cream by Community Pharmacists in Somerset to patients for the topical treatment of minor localised impetigo under the Somerset Minor Ailments
More informationCLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES
CLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu THE AMINOGLYCOSIDES: 1944-1975 Drug
More informationSepticaemia Definitions 1
Septicaemia Definitions 1 Term Definition Bacteraemia Systemic Inflammatory response (SIRS) Sepsis Bacteria that can be cultured from the blood stream The systemic response to a wide range of stresses.
More informationCHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
CHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Antibiotics One of the most commonly used group of drugs In USA 23
More informationAmerican Association of Feline Practitioners American Animal Hospital Association
American Association of Feline Practitioners American Animal Hospital Association Basic Guidelines of Judicious Therapeutic Use of Antimicrobials August 1, 2006 Introduction The Basic Guidelines to Judicious
More informationWho should read this document? 2. Key practice points 2. Background/ Scope/ Definitions 2. What is new in this version? 3
Neurosurgical infections (adult only) Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): as above Authors Division: DCSS & Tertiary
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. 10. Treatment of peritoneal dialysis associated fungal peritonitis
10. Treatment of peritoneal dialysis associated fungal peritonitis Date written: February 2003 Final submission: July 2004 Guidelines (Include recommendations based on level I or II evidence) The use of
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More informationAntibiotic Guideline: Empirical Treatment of Bone and Joint Infection in Adults
Antibiotic Guideline: Empirical Treatment of Bone and Joint Infection in Adults Document type: Prescribing guideline Version: 5.0 Author (name and designation) Samim Patel, Antimicrobial Lead Pharmacist
More informationHost, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus
Host, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus Montana ACP Meeting 2018 September 8, 2018 Staci Lee, MD, MEHP Billings
More informationAntimicrobial utilization: Capital Health Region, Alberta
ANTIMICROBIAL STEWARDSHIP Antimicrobial utilization: Capital Health Region, Alberta Regionalization of health care services in Alberta began in 1994. In the Capital Health region, restructuring of seven
More informationStaphylex Flucloxacillin (sodium)
Staphylex Flucloxacillin (sodium) PRODUCT INFORMATION Name of the Medicine Flucloxacillin sodium is the sodium salt of 3-(2'-chloro-6'-fluorophenyl)-5-methyl-4-isoxazolylpenicillin monohydrate. Structural
More informationUPDATE ON ANTIMICROBIAL STEWARDSHIP REGULATIONS AND IMPLEMENTATION OF AN AMS PROGRAM
UPDATE ON ANTIMICROBIAL STEWARDSHIP REGULATIONS AND IMPLEMENTATION OF AN AMS PROGRAM Diane Rhee, Pharm.D. Associate Professor of Pharmacy Practice Roseman University of Health Sciences Chair, Valley Health
More informationNeurosurgery Antibiotic Prophylaxis Guideline
Neurosurgery Antibiotic Prophylaxis Guideline Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review date (when this version
More informationChapter 51. Clinical Use of Antimicrobial Agents
Chapter 51 Clinical Use of Antimicrobial Agents History of antimicrobial therapy Early 17 th century Cinchona bark was used as an important historical remedy against malaria. 1909 Paul Ehrlich sought a
More informationProduct Information GENTAMICIN INJECTION BP NAME OF THE DRUG DESCRIPTION PHARMACOLOGY. Gentamicin Sulfate BP.
Product Information GENTAMICIN INJECTION BP NAME OF THE DRUG Gentamicin Sulfate BP. DESCRIPTION Gentamicin sulfate is a mixture of the sulfates of antimicrobial substances produced by Micromonospora purpurea.
More information4 th and 5 th generation cephalosporins. Naderi HR Associate professor of Infectious Diseases
4 th and 5 th generation cephalosporins Naderi HR Associate professor of Infectious Diseases Classification Forth generation: Cefclidine, cefepime (Maxipime),cefluprenam, cefoselis,cefozopran, cefpirome
More informationUSA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION
VIRBAC CORPORATION USA Product Label http://www.vetdepot.com P.O. BOX 162059, FORT WORTH, TX, 76161 Telephone: 817-831-5030 Order Desk: 800-338-3659 Fax: 817-831-8327 Website: www.virbacvet.com CLINTABS
More informationDBL GENTAMICIN INJECTION BP
DBL GENTAMICIN INJECTION BP NAME OF THE MEDICINE Gentamicin Injection BP DESCRIPTION DBL Gentamicin Injection BP is a sterile solution containing in each ml: Gentamicin Sulphate BP equivalent to gentamicin
More informationAntibiotic Usage Guidelines in Hospital
SUPPLEMENT TO JAPI december VOL. 58 51 Antibiotic Usage Guidelines in Hospital Camilla Rodrigues * Use of surveillance data information of Hospital antibiotic policy guidelines from Hinduja Hospital. The
More informationEuropean Public MRL assessment report (EPMAR)
18 March 2016 EMA/CVMP/619817/2015 Committee for Medicinal Products for Veterinary Use European Public MRL assessment report (EPMAR) Gentamicin (all mammalian food producing species and fin fish) On 3
More informationDisclosures. Principles of Antimicrobial Therapy. Obtaining an Accurate Diagnosis Obtain specimens PRIOR to initiating antimicrobials
Disclosures Principles of Antimicrobial Therapy None Lori A. Cox MSN, ACNP-BC, ACNPC, FCCM Penn State Hershey Medical Center Neuroscience Critical Care Unit Obtaining an Accurate Diagnosis Determine site
More informationCystic Fibrosis- management of Burkholderia. cepacia complex infections
Guideline Cystic Fibrosis- management of Burkholderia cepacia complex infections Key messages Burkholderia cepacia infections are associated with significant adverse outcomes in Cystic Fibrosis patients
More informationConsider the patient, the drug and the device how do you choose?
Consider the patient, the drug and the device how do you choose? Tim Hills Lead Pharmacist Antimicrobials and Infection Control Nottingham University Hospitals NHS Trust OPAT Recommendations Drug Therapy
More informationRecommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland
Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland A report by the Hospital Antimicrobial Stewardship Working Group, a subgroup of the
More informationClinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: Oregon Health Plan
Clinical Policy: (Zyvox) Reference Number: CP.PMN.27 Effective Date: 07.01.18 Last Review Date: 05.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end of this policy
More informationin Plastic Container Gentamicin Sulfate in 0.9% Sodium Chloride Injection
Gentamicin Sulfate in 0.9% Sodium Chloride Injection in Plastic Container VIAFLEX Plus Container For Intravenous Administration Further Dilution Not Required Rx Only To reduce the development of drug-resistant
More informationAntibiotic Stewardship in the LTC Setting
Antibiotic Stewardship in the LTC Setting Joe Litsey, Director of Consulting Services Pharm.D., Board Certified Geriatric Pharmacist Thrifty White Pharmacy Objectives Describe the Antibiotic Stewardship
More informationCOMPLIANCE WITH THIS DOCUMENT IS MANDATORY
COVER SHEET NAME OF DOCUMENT Sepsis Pathway Emergency Department TYPE OF DOCUMENT Procedure DOCUMENT NUMBER ISLHD CLIN PROC 137 DATE OF PUBLICATION October 2016 RISK RATING Medium REVIEW DATE October 2018
More informationCommonwealth of Kentucky Antibiotic Stewardship Practice Assessment For Long-Term Care Facilities
Commonwealth of Kentucky Antibiotic Stewardship Practice Assessment For Long-Term Care Facilities Introduction As the problem of antibiotic resistance continues to worsen in all healthcare setting, we
More information